(PharmaNewsWire.Com, December 23, 2017 ) Testosterone replacement therapy, also called androgen replacement therapy, is typically used to treat hypogonadism. Testosterone, a hormone produced by the testes, is responsible for the development of secondary sexual characters in men. The levels of testosterone decrease gradually with age, but sometimes this decline is seen even in young men, leading to a condition known as hypogonadism. This can be treated with external supply of testosterone in the form of gels, patches, injectable, or oral drugs. Publisher's analysts forecast the global testosterone replacement therapy market is gradually declining and will post a CAGR of (3.35) % during the period 2016-2020.
Covered in this report The report covers the present scenario and the growth prospects of the global testosterone replacement therapy market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs that treat and prevent hypogonadism.
The market is divided into the following segments based on geography: - Americas - APAC - EMEA
Publisher's report, Global Testosterone Replacement Therapy Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors - AbbVie - Allergan - Eli Lilly and Company - Endo Pharmaceuticals
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
